ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• To Counter Bias, Counterbalance

  It’s easy to overlook the effects a survey’s format can have on responses, but those effects are potent sources of bias. Modern EDC allows you to systematically vary both question and response option order. This practice, called counterbalancing, guards against unwanted order effects.

• Guide: Switching To A New EDC System

  Read to learn five key tips when switching to a new EDC system, including best practices for change management, process and people training, KPIs, and more.

• Growing Pains: The Real Story Behind Gen AI Development In Clinical Trial Ops

  As Gen AI develops and reaches advanced stages it introduces risks such as model hallucinations, which can affect trial accuracy and reliability. Explore how to address these challenges.

• Overcoming 5 Challenges Of Implementing eClinical Technologies

  Assess five common pitfalls trial teams face when incorporating new technology and identify potential solutions to mitigate the common risks.

• Building A Gold Standard Trial Experience In Japan

  Hear how Medable worked with a Japanese sponsor to elevate their trial experience, achieve >90% patient and site adherence, and beat their forecasted FPI date, creating new eCOA standards adopted across all the customer’s vendors.

• RBQM For Decentralized Trials: Two Key Areas Of Focus To Reduce Your Risk

  This article takes a more in-depth look at Sections 5.0.5: ‘Risk Communication’ and 5.0.6: ‘Risk Review.’ in ICH-GCP E6 R2 to show how the implementation of RBQM can reduce issues and achieve holistic trial oversight in today’s complex decentralized trials.

• Kicking Off A Clinical Trial The Right Way - With Seamless Digital Consent

  Read this blog to learn more about how eConsent can enhance participant engagement and retention when used both onsite and remotely.

• Defining 'Evidence Generation' Within Modern Clinical Trials

  Learn how this distinctive approach centered on enabling clinical trial sponsors to gather data and generate evidence ensures the successful acquisition of diverse information.

• The Strategic Role Of KOLs In Rare Disease Drug Development

  Engaging key Opinion Leaders (KOL) is crucial for accelerating rare disease research breakthroughs. However, identifying the right experts is challenging due to fragmented data and evolving expertise.

• Partnership Driving Superior Enrollment And Speed In Phase III Trial

  Examine the partnership between CRIO and Sitero, including how it underscores the significant impact of technology in optimizing trial performance and accelerating treatment development.